The Memo | Special Edition: Medtech Trailblazers Heading to LSI USA '26

Each week in The Memo, we spotlight one emerging medtech company pushing the boundaries of what’s possible in patient care. This week, we’re doing something different. With LSI USA ’26 just two weeks away, we’re featuring a special edition highlighting a select group of trailblazing companies across five major market segments, all of whom will take the stage in Dana Point.

This is only a snapshot of the companies presenting at LSI USA ’26, but it offers a compelling preview of the innovation that will be on display.

*Note: All information included in this article is sourced from the LSI USA ’26 Startup Profiles spreadsheet, Compass AI, and the LSI USA ’26 Presenting Companies page.

Cardiovascular

Fluid Biomed

Presenter: John Wong

Company Description: Fluid Biomed is developing the world’s first bioabsorbable stent to treat brain aneurysms. The company’s innovative polymer technology allows physicians the versatility of treating a wider variety of aneurysms more safely and efficiently.

Stage: Undisclosed

Commercial Status: Clinical (Pre-Revenue)

Strategic Landscape: Boston Scientific, Stryker, Terumo

4C Medical Technologies

Presenter: Saravana Kumar

Company Description: 4C Medical’s AltaValve is a supra-annular transcatheter mitral valve replacement (TMVR) system. The AltaValve system is intended to streamline the procedure to replace degenerated mitral valves compared to current solutions.

Stage: Later Stage

Commercial Status: Clinical (Pre-Revenue)

Strategic Landscape: Medtronic, Boston Scientific, Abbott, Edwards

StimCardio Medical (FKA CardiaCare)

Presenter: Amir Soltanianzadeh

Company Description: StimCardio Medical is developing a breakthrough neuromodulation wearable therapy for AFib that combines peripheral neurostimulation with closed-loop, AI-enabled monitoring.

Stage: Series A

Commercial Status: Clinical (Pre-Revenue)

Strategic Landscape: Medtronic, Boston Scientific, Abbott, LivaNova

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-special-edition-medtech-trailblazers-heading-to-lsi-usa-26

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more